Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Novo Nordisk A/S (NVO) is having one of its best days in more than two months, with shares popping 2.58% -- their highest percentage gain since May 2 -- shortly after the market opened Thursday. NOV added $1.18 to $46.83 after Novo Nordisk released positive late-stage test results for two drugs designed to treat diabetes.

The drugs, PIONEER 4 and PIONEER 7, both met analyst expectations for reducing the amount of a protein that affects people's blood-sugar levels, but "demonstrated statistically significant and superior reductions in body weight" when compared to competitors, Nova Nordisk said in a statement.

Jefferies analysts estimate the drugs could enjoy $4.5 billion in peak sales if the substances win U.S. Food and Drug Administration approval, according to Bloomberg data.

More from Stocks

Oil Prices, Barrick Gold, Randgold, Comcast, Tiger Woods- 5 Things You Must Know

Oil Prices, Barrick Gold, Randgold, Comcast, Tiger Woods- 5 Things You Must Know

Barrick Gold and Randgold Resources in Advance Merger Talks: Reports

Barrick Gold and Randgold Resources in Advance Merger Talks: Reports

How Investors Can Profit by Focusing on This One Key Business Statistic

How Investors Can Profit by Focusing on This One Key Business Statistic

The Easy Money in Amazon Stock Has Been Made

The Easy Money in Amazon Stock Has Been Made

Is the Cannabis Crazy Equivalent to the Dot Com Bubble?

Is the Cannabis Crazy Equivalent to the Dot Com Bubble?